Related Experiment Video
Updated: Aug 9, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Criteria for discontinuing neonatal seizure therapy: a long-term appraisal
Insights
Discontinuing neonatal anticonvulsant treatment requires careful evaluation of seizure control and EEG abnormalities. Persistent EEG abnormalities are key to guiding treatment duration and discontinuation in newborns.
Area of Science:
- Neonatal neurology
- Pediatric epilepsy
Background:
- Neonatal seizures are a common neurological problem in newborns.
- Anticonvulsant treatment is often necessary but carries potential risks.
- Establishing clear criteria for discontinuing treatment is crucial.
Purpose of the Study:
- To evaluate criteria for discontinuing anticonvulsant treatment in newborns with seizures.
- To identify key variables influencing treatment duration and cessation.
Main Methods:
- Studied 55 newborns with seizures, performing serial clinical and EEG examinations.
- Treatment with phenobarbital was discontinued based on seizure characteristics, EEG findings, and etiology.
- Follow-up assessments were conducted for up to 8 years.
Main Results:
- Only 4 out of 55 children relapsed after treatment discontinuation.
- Relapses were generally mild and often without EEG abnormalities.
- Persistence of EEG abnormalities was the most significant factor in planning treatment duration.
Conclusions:
- The employed criteria for discontinuing neonatal anticonvulsant therapy are effective.
- EEG abnormality persistence is the most critical factor for guiding treatment decisions.
- This study provides evidence-based guidelines for managing neonatal seizures.
Abstract:
In order to evaluate the criteria for discontinuing neonatal anticonvulsant treatment, 55 newborns with seizures have been studied. Clinical and EEG serial examinations were performed: soon after the first seizure, throughout the hospital course, and during the follow-up every 3 months until a year, and every 6 months later on. Anticonvulsant treatment with phenobarbital was discontinued (at 4 days-19 months; mean 104 days) on the basis of the following variables: type and number of seizures, time taken for their control, type and persistence of EEG abnormalities, initial neurological features, and seizure etiology. At the follow-up (12 months-8 years; mean 36 months) only 4 children had relapsed, 3 of them with a single short seizure without EEG abnormalities. The results obtained by means of the correlation between the length of anticonvulsant treatment and the clinical and EEG variables provide evidence of the value of the criteria employed. Of these, the duration of persistence of EEG abnormalities was the most important for planning the maintenance of anticonvulsant treatment and its discontinuation.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Electroconvulsive Therapy
Seizures l: Introduction

